AbCellera FY2024 revenue $28.8M (down 24%), net loss $0.55/share; plans Phase 1 for two programs in 2025

AbCellera Biologics Inc.

2024-FY EPS reported -$0.55 revenue$28,833,000

Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.
Cash, securities and non-dilutive govt funding total approx. $840M in available liquidity.
Cumulative partner program starts up to 96 (87 in 2023); 16 molecules in clinic (13 in 2023).
Plans to initiate Phase 1 trials for ABCL635 and ABCL575 and start clinical manufacturing facility in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.